Literature DB >> 33110014

A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles.

Christopher J Black1,2, Yan Yiannakou3, Elspeth A Guthrie4, Robert West4, Lesley A Houghton2, Alexander C Ford1,2.   

Abstract

INTRODUCTION: Conventionally, patients with irritable bowel syndrome (IBS) are subgrouped based on their predominant bowel habit. Given the relevance of psychological comorbidity to IBS symptoms, our aim was to explore an alternative approach to subgrouping by incorporating factors beyond stool form and frequency.
METHODS: We collected demographic, symptom, and psychological health data from 1,375 adult subjects in the community who self-identified as having IBS, identifying 2 cohorts meeting either Rome III or Rome IV criteria. In each cohort, we performed latent class analysis, a method of model-based clustering, to identify specific subgroups (clusters). For each cluster, we drew a radar plot and compared these by visual inspection, describing cluster characteristics.
RESULTS: In total, 1,080 individuals met the Rome III criteria for IBS, and 811 met the Rome IV criteria. In both cohorts, a 7-cluster model was the optimum solution, and the characteristics of the clusters were almost identical between Rome III and IV. Four clusters were defined by the pattern of gastrointestinal symptoms (loose stools and urgency or hard stools and bloating), further differentiated by the presence of abdominal pain not relieved by defecation, and by the extent of psychological comorbidity. Two clusters had below-average gastrointestinal symptoms, differentiated by the extent of psychological comorbidity. The final cluster had well-above-average gastrointestinal symptoms and high levels of psychological comorbidity. The proportion of subjects with severe IBS symptom scores, high levels of perceived stress, and high levels of gastrointestinal symptom-specific anxiety was significantly higher in clusters with high psychological comorbidity (P < 0.001). DISCUSSION: Latent class analysis identified 7 distinct IBS subgroups characterized by varying degrees of gastrointestinal symptoms, extraintestinal symptoms, and psychological comorbidity. Further research is needed to assess whether they might be used to direct treatment.
Copyright © 2020 by The American College of Gastroenterology.

Entities:  

Year:  2021        PMID: 33110014     DOI: 10.14309/ajg.0000000000000975

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

1.  Experience and clinical efficacy of gut-directed hypnotherapy in an Asian population with refractory irritable bowel syndrome.

Authors:  Ayodele Sasegbon; Syed S Hasan; Peter J Whorwell; Dipesh H Vasant
Journal:  JGH Open       Date:  2022-05-19

2.  Defining the irritable bowel.

Authors:  Kee Huat Chuah; Sanjiv Mahadeva
Journal:  JGH Open       Date:  2022-04-20

3.  The symptom burden of Irritable Bowel Syndrome in tertiary care during the COVID-19 pandemic.

Authors:  Hithin Noble; Syed Shariq Hasan; Peter J Whorwell; Dipesh H Vasant
Journal:  Neurogastroenterol Motil       Date:  2022-03-03       Impact factor: 3.960

4.  Volatile organic compound profiling as a potential biomarker in irritable bowel syndrome: A feasibility study.

Authors:  Kathleen Van Malderen; Nikita Hanning; Helen Lambrechts; Tine Haverhals; Silke Van Marcke; Hannah Ceuleers; Joris G De Man; Benedicte Y De Winter; Kevin Lamote; Heiko U De Schepper
Journal:  Front Med (Lausanne)       Date:  2022-08-04

5.  Studies on irritable bowel syndrome associated with anxiety or depression in the last 20 years: A bibliometric analysis.

Authors:  Yuanfang Chen; Baotao Lian; Peize Li; Simeng Yao; Zhengkun Hou
Journal:  Front Public Health       Date:  2022-08-15

6.  Development and validation of audio-based guided imagery and progressive muscle relaxation tools for functional bloating.

Authors:  Vincent Tee; Garry Kuan; Yee Cheng Kueh; Nurzulaikha Abdullah; Kamal Sabran; Nashrulhaq Tagiling; Nur-Fazimah Sahran; Tengku Ahmad Iskandar Tengku Alang; Yeong Yeh Lee
Journal:  PLoS One       Date:  2022-09-26       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.